Am J Ophthalmol
Tirzepatide associated with lower glaucoma, ocular hypertension risk
In a nationwide retrospective cohort of adults with T2DM, initiation of tirzepatide was associated with significantly lower risks of primary open-angle glaucoma, ocular hypertension, and need for glaucoma treatment compared with selective GLP‑1 RAs. The analysis included 41,849 matched patients per group and excluded those with prior glaucoma or ocular trauma. Risk reductions persisted in subgroups using metformin or insulin, and sensitivity analyses in older adults and comparisons with semaglutide and dulaglutide showed consistent trends. These findings suggest tirzepatide may confer additional ocular benefits beyond glycemic and cardiometabolic effects.
Clinical takeaway: Consider potential ocular advantages when selecting incretin-based therapy for patients with T2DM.
Source:
Hong AT, et al. (2025, December 6). Am J Ophthalmol. Tirzepatide is Associated with Reduced Risk of Primary Open-Angle Glaucoma and Ocular Hypertension in Patients with Type 2 Diabetes. https://pubmed.ncbi.nlm.nih.gov/41360342/